Healthcare / BiotechnologyNasdaqGS
$1.36
-0.06 (-4.23%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-46.5M · quality 52.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
8/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$169M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-151.0%
↓Gross Margin
N/A
•Debt/Equity
1.40
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2018–2025 · 7 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-3191.7%
FCF / Net income
0.78x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.5M · net income $-63.1M · FCF $-49.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | $1.5M | $1.5M | — | $1.0M | $5.0M | — | — | — | — |
| Net Income | $-63.1M | $-63.1M | $-41.5M | $-59.7M | $-58.4M | $-42.9M | $-50.0M | $-55.2M | $-23.2M |
| EBITDA | $-59.1M | $-59.1M | $-37.8M | $-57.0M | $-58.3M | $-43.0M | $-50.6M | $-57.8M | $-23.8M |
| EPS | — | — | -0.67 | -1.39 | -1.38 | -1.02 | -1.70 | — | — |
| Operating Margin | -4019.4% | -4019.4% | — | -6109.8% | -1192.8% | — | — | — | — |
| Net Margin | -4078.8% | -4078.8% | — | -5968.5% | -1167.8% | — | — | — | — |
| Balance Sheet | |||||||||
| Debt/Equity | 1.40 | 1.40 | 4.17 | 3.09 | 0.04 | — | — | 0.00 | — |
| Current Ratio | 8.01 | 8.01 | — | — | — | — | — | — | — |
| Cash Flow | |||||||||
| Free Cash Flow | $-49.3M | $-49.3M | $-28.9M | $-46.5M | $-52.7M | — | — | $-51.6M | $-21.1M |
| Returns | |||||||||
| ROE | -151.0% | -151.0% | -315.8% | -355.9% | -88.0% | -38.1% | -34.9% | -48.1% | -27.8% |
| Valuation | |||||||||
| P/B | 3.46 | 3.46 | 10.41 | 4.41 | 2.48 | — | — | — | — |
| Growth & Yield | |||||||||
| Revenue Growth | — | — | — | -80.0% | — | — | — | — | — |
| EPS Growth | — | — | 51.8% | -0.7% | — | 40.0% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-16.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.67 → n/d
Residual
-16.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.